#Denmark #Lundbeck #Valby #Vyepti #Rexulti

Lundbeck Boosts Full-Year Projections Following Impressive 9-Month Growth

In a significant development for the pharmaceutical sector, H. Lundbeck A/S has announced an upward revision of its full-year revenue and adjusted EBITDA forecasts for 2026. The decision follows a robust performance in the first nine months of the year, during which the company recorded an impressive 13% increase in revenue, amounting to DKK 20,191 million. This growth can largely be attributed to the strong market performance of their product, Vyepti®, alongside solid contributions from other key offerings like Rexulti®.

Performance Overview

With growth observed across all regions, Lundbeck's strategic focus on key markets appears to be paying dividends. The company's European operations demonstrated a strong performance, recording DKK 4,714 million, representing a 9% increase. International operations also saw a steady rise, reaching DKK 4,000 million. Notably, revenue from Lundbeck’s strategic brands, which includes Vyepti®, Rexulti®, and others, rose by 16% in constant exchange rates, illustrating the effectiveness of Lundbeck's marketing strategies.

Breakdown of Revenue Growth

The detailed performance metrics present a clear picture:

• - Vyepti®: DKK 4,533 million (+45% CER)
• - Rexulti®: DKK 5,071 million (+13% CER)
• - Brintellix®/Trintellix® garnered DKK 3,389 million (flat growth)
• - Abilify LAI franchise reached DKK 2,958 million (+6% CER)

These figures demonstrate not only Lundbeck's effective product positioning but also the growing demand for its therapeutic solutions. The impressive growth of Vyepti®, in particular, emphasizes its status as a critical component of the company’s portfolio, especially in the context of migraine treatment.

Adjusted EBITDA and EPS Growth

Financially, Lundbeck is performing well, with adjusted EBITDA rising to DKK 7,026 million, reflecting a 19% increase when measured in constant exchange rates. This upward trajectory is buoyed by better operational efficiencies despite the upfront costs associated with transitioning to a partnership model in 27 markets that has been described as "proceeding according to plan". Lundbeck’s EPS also saw a notable uptick, reaching DKK 4.11, marking a 30% increase compared to the same period last year.

Strategic Initiatives and Future Outlook

Reflecting on these results, Lundbeck’s President and CEO, Charl van Zyl, stated that the continuous strong performance of Vyepti® greatly reinforces their decision to raise the company's outlook for the full year. Moreover, he pointed out that the recent approval of Vyepti® in Japan further solidifies Lundbeck's international footprint in the migraine therapy sector. The upcoming milestones within their pipeline, including studies for bexicaserin and amlenetug, align with Lundbeck's strategic focus on innovation and growth.

In recognition of this positive momentum, Lundbeck has officially revised its guidance, now expecting revenue growth between 11% and 12% for the year, significantly higher than previously anticipated. Similarly, adjusted EBITDA growth expectations have been adjusted to 15%-19%.

Recent Developments

Recent announcements from Lundbeck have included management changes and the establishment of a global innovation hub in Greater Boston, reflecting their commitment to enhancing their operational capacity in a leading life sciences environment. The company is also focusing on key pipeline developments, highlighting its commitment to research and development.

As Lundbeck continues to navigate the evolving pharmaceutical landscape, these developments and their strategic adjustments suggest a proactive approach to maintaining growth and innovation in the coming years. Investors and market spectators will be keen to observe how these strategies unfold heading into 2027, particularly as Lundbeck transitions into the Scale phase of its Focused Innovator Strategy.